|
26th June
|
Day 1
|
|
|
|
|
1200
|
Registration Lunch and refreshments
|
|
1300
|
Welcome Address – Julian Downward
|
|
1315
|
Opening Keynote:
Charles Swanton (Francis Crick Institute, London)
Cancer evolution, immune evasion and metastasis
|
|
|
Session 1: New Technologies, Engineering and Imaging
Chairs: Richard Bayliss and Charlotte Bevan
|
|
1400
|
BACR/AstraZeneca Frank Rose Award Talk
Vivian Li (Francis Crick Institute, London
Colorectal cancer targeting and intestinal bioengineering
|
|
1430
|
Tony Ng (King’s College London)
Integrative imaging-OMIC combination approach to probe tumour cell/microenvironment changes for recurrent cancer detection and treatment
|
|
1500
1515
|
Greg Wells (Sheffield)
Utilising ex vivo imaging to measuring drug action at the single cell level using a live biopsy
Pamela Collier (Nottingham)
Bioluminescent labelling of patient-derived xenografts to enable monitoring of orthotopic and metastatic growth
|
| |
|
|
1530
|
Afternoon tea/coffee
|
|
|
|
|
|
|
|
1600
|
Carolyn Moores (Birkbeck, University of London)
Studying the microtubule mitotic machinery using cryo-EM
|
|
1630
|
Faith Howard (University of Sheffield)
BACR/Astex Pharmaceuticals Roger Griffin Prize for Drug Discovery
Nanobugs as Drugs: Bacterial Derived Nanomagnets Enhance Tumor Targeting and Oncolytic Activity of HSV-1 Virus
|
|
1700
|
Zoltan Takats (Imperial College London)
Molecular interaction network-based disease models: Outlines of a coherent and comprehensive cancer care system
|
|
1730
1900
|
Welcome drinks and finger buffet 
Sponsored by Worldwide Cancer Trials
Poster Session 1 (Even Numbers)
Speakers Dinner
|
|
27th June
|
Day 2
Session 2: Tumour Microenvironment and Immunotherapy
Chairs: Robert Wilkinson and Anna Grabowska
|
|
0830
|
Gareth Thomas (Southampton)
Targeting cancer-associated fibroblasts to overcome immunotherapy resistance
|
|
0900
|
Ilaria Malanchi (Francis Crick Institute, London)
Neutrophils nurturing the tumour microenvironment
|
|
0930
|
Timothy Budden (University of Manchester)
BACR Chris Marshall Prize for Cell Signalling
Sex and ageing in skin cancer
|
|
1000
|
Martina Brucoli (Glasgow)
Addressing a non-cell autonomous tumour suppressive role for Dram1 in inflammation-induced colorectal cancer
|
|
1015
|
Claire Reader (F-Star Therapeutics, Babraham)
FS118, a novel LAG-3/PD-L1 bispecific antibody, reduced cell-surface LAG-3 and induced LAG-3 shedding through tetravalent target binding
|
|
|
|
|
1030
|
Tea/Coffee
|
|
|
|
|
1100
|
Ignacio Melero (University of Navarra, Spain)
IL-8 and NETs in cancer
|
|
1130
|
Christophe Caux (Lyon Cancer Research Centre, France)
Dendritic cells and NK cells in tumor immune surveillance”
|
|
|
|
|
12.00
|
Lunch Posters and Exhibition
(12.10 to 12.30 Commercial Workshop Given by Greiner)
|
|
|
|
|
|
Session 3: Resistance to Therapy
Chairs: Isabel Pires and Kevin Ryan
|
|
1330
|
Ester Hammond (Oxford)
Targeting the hypoxia-induced DNA damage response
|
|
1400
|
Mike Hemann (MIT, Cambridge, USA)
Understanding Resistance to Cell-Based Immunotherapy
|
|
1430
|
Martin Miller (AstraZeneca, Cambridge)
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
|
|
1445
|
Deborah Caswell (Francis Crick Institute, London)
The role of APOBEC3B in lung tumour evolution and targeted therapy resistance
|
| |
|
| |
|
|
1500
|
Tea/Coffee
|
|
|
|
|
1530
|
Anthony Letai (Dan-Farber, Boston USA)
Measuring mitochondrial apoptotic signaling to direct patient care
|
|
1600
|
Thomas Helleday (Karolinska Institutet, Stockholm)
Targeting DNA repair through metabolism
|
|
1630
|
Val Macaulay (Oxford)
Investigating IGFs as mediators of therapy resistance
|
|
1700
1900
|
Drinks Reception
Poster Session 2 (Odd Numbers)
Conference Dinner
|
|
28th June
|
Day 3
Session 4: Signalling Networks
Chairs: Amanda Harvey and Claire Perks
|
|
0830
|
Angel Nebreda (IRB Barcelona, Spain)
Exploring tumor vulnerabilities by targeting stress kinase signaling
|
|
0900
|
Stephen Tait (Beatson, Glasgow)
Targeting cell death associated inflammation in cancer
|
|
0930
|
Natalia Riobo-DelGaldo (Leeds)
PTCH1 C-terminal domain mutations enhance colon cancer tumorigenesis
|
|
0945
|
Sabrina Zema (Sapienza University, Rome, Italy)
Identification of Maml1 as a novel negative regulator of Itch E3
|
|
1000
|
Dafna Bar-Sagi (New York University, USA)
|
|
1030
|
Manolis Pasparakis (Cologne, Germany)
Inflammatory signalling in small cell lung cancer
|
|
|
|
|
1100
|
Tea/Coffee
|
|
|
|
|
1130
|
Len Stephens (Babraham)
Signalling via PI3Ks and Plekhs1 in a mouse model of prostate tumour progression
|
|
|
|
|
|
Session 5: Disruptive Science and the future
Chairs: Barry Davies and Simon Dovedi
|
|
1200
|
Bernd Bodenmiller (Zurich, Switzerland)
|
|
12.30
|
Highly multiplexed imaging of tissues with subcellular resolution by imaging mass cytometry
Nicholas Brittain (Newcastle)
Combining novel CRISPR-Cas13 & proximity biotinylation methods for proteomic identification of AR-V7 mRNA splicing regulators in castrate resistant prostate cancer
|
|
12.45
|
Megan Cole (Francis Crick Institute, London)
Spatial proteomic analysis of a NSCLC model revealed regulatory T cells as mediators of KRAS-G12C-inhibitor-dependent immune response
|
| |
|
|
1300
|
Lunch Posters and Exhibition
|
|
1400
1430
|
Nitzan Rosenfeld (Cambridge)
Expanding roles of liquid biopsies for cancer diagnostics
Raj Chopra (ATP, London)
Reprogramming protein homeostasis using small molecule modulators of E3 ligases
|
| |
|
|
1500
|
George Poulogiannis (The Institute of Cancer Research, London)
BACR/AstraZeneca Frank Rose Award (2022)
Dissecting the role of metabolism and nutrition in P13K-induced
oncogenicity
|
|
1530
|
Tea/Coffee
|
|
1600
|
Closing Keynote:
|
|
|
Kevan Shokat (UCSF,USA)
Overcoming the Undruggable Nature of Oncogenic K-Ras
|
|
1645
|
Closing Remarks, Proffered Paper Awards Given
|
|
1700
|
Meeting Closes
|
